Understanding and harnessing the graft‐versus‐leukaemia effect
Open Access
- 21 August 2008
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 142 (6), 877-888
- https://doi.org/10.1111/j.1365-2141.2008.07260.x
Abstract
The graft‐versus‐leukaemia (GVL) effect is a central component of the stem cell allograft’s ability to cure haematological malignancies. The GVL effect is mediated by donor‐derived natural killer cells and T lymphocytes, which have distinct mechanisms of recognizing and targeting the recipient’s malignant cells. After transplantation the cytokine milieu is favourable to the early establishment of a GVL effect, but the need to prevent graft‐versus‐host disease limits the full potential of this process. Clinical studies have identified some critical components of the transplant preparation, donor selection, stem cell source (peripheral blood versus bone marrow) and post‐transplant management that can be manipulated to optimize the GVL effect. However, further developments focusing on the selective depletion of unwanted alloreactivity with preservation of GVL effects, and the use of vaccines or the adoptive transfer of leukaemia‐specific lymphocytes, will be required to enhance the GVL effect to reliably eradicate more resistant leukaemias.Keywords
This publication has 96 references indexed in Scilit:
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesJCI Insight, 2008
- Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignanciesBlood, 2008
- IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunityBlood, 2007
- Graft-versus-leukemia effects associated with detectable Wilms tumor-1–specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemiaBlood, 2007
- Translational Mini-Review Series on Vaccines:
Peptide vaccines for myeloid leukaemiasClinical and Experimental Immunology, 2007
- Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantationBlood, 2006
- High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCTBlood, 2006
- Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disordersBone Marrow Transplantation, 2006
- Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsBlood, 2006
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979